,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['bcsm']
#asco22 #bcsm dr. presents safety f/u data from db-03 trial: 10.9% all-grade ild in t-dxd vs 1.9% for t-dm1, 8% discontinued t-dxd due to ild. median time to ild: 181d (range: 33-507d). 57% of pts w/ ild had recovered/resolved at time of data cutoff. 
Internist & oncologist serving ppl w/ cancer @ #bcsm clinic, #MedEd, #Regulatory & #COVID19. #ASCO20 Ed Chair. @HCWvsHunger. Not afraid to speak up. Go high.